A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

Source:http://linkedlifedata.com/resource/pubmed/id/15070664

Blood 2004 Apr 15 103 8 2920-4

Download in:

View as

Triples

General Info

PMID
15070664